Cumberland Pharmaceuticals Inc.
CPIX
$3.40
$0.144.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.04% | 37.84% | 24.49% | -9.92% | -9.55% |
| Total Other Revenue | -- | -- | -34.76% | -- | -- |
| Total Revenue | 10.04% | 37.84% | 11.57% | -9.92% | -9.55% |
| Cost of Revenue | 17.56% | -9.51% | 29.18% | -25.07% | 12.50% |
| Gross Profit | 8.46% | 48.61% | 8.13% | -6.70% | -13.13% |
| SG&A Expenses | 1.33% | 2.64% | -7.92% | -0.20% | -0.52% |
| Depreciation & Amortization | -8.49% | -9.49% | 22.09% | -8.25% | -5.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.52% | 0.52% | 0.73% | -9.81% | 0.09% |
| Operating Income | 27.19% | 169.11% | 35.04% | 9.23% | -4,583.41% |
| Income Before Tax | 33.15% | 166.31% | 68.80% | -44.42% | -225.56% |
| Income Tax Expenses | -50.00% | -50.00% | -328.00% | 65.22% | 65.22% |
| Earnings from Continuing Operations | 33.32% | 165.61% | 69.83% | -44.56% | -227.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -132.35% | 120.32% | -128.95% | -151.08% | 70.00% |
| Net Income | 31.77% | 164.59% | 69.75% | -47.16% | -224.47% |
| EBIT | 27.19% | 169.11% | 35.04% | 9.23% | -4,583.41% |
| EBITDA | 153.90% | 423.34% | 78.43% | 6.78% | -90.78% |
| EPS Basic | 35.63% | 160.90% | 69.33% | -49.52% | -226.90% |
| Normalized Basic EPS | 34.61% | 160.99% | 31.89% | -30.63% | -222.66% |
| EPS Diluted | 37.50% | 157.14% | 68.51% | -49.66% | -233.33% |
| Normalized Diluted EPS | 34.61% | 159.72% | 31.89% | -30.63% | -223.95% |
| Average Basic Shares Outstanding | 5.97% | 5.99% | -1.36% | -1.57% | -1.91% |
| Average Diluted Shares Outstanding | 5.97% | 8.24% | -1.36% | -1.57% | -3.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |